Research Progress on Glypican-3 Targeted Therapy in Hepatocellular Carcinoma

VernacularTitle:磷脂酰肌醇蛋白聚糖-3靶向治疗肝细胞癌的研究进展
Author: Yuxin FANG ¹ ; Yu LI ¹ ; Baoshu LIU ¹ ; Guoqiang DONG ¹
Author Information

1. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
Keywords: Hepatocellular carcinoma; Glypican-3; signaling pathway; HCC therapy
From: Journal of Pharmaceutical Practice 2023;41(10):586-593
CountryChina
Language:Chinese
Abstract: Liver cancer is the second leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) being the most common form of primary liver cancer. Glypican-3 (GPC3) is a cell membrane proteoglycan which is rarely expressed in normal adult tissues but is specifically upregulated in HCC, which makes GPC3 a reliable target for the diagnosis and treatment of HCC. The role of GPC3 in the regulation of cancer development through Wnt, YAP, hedgehog and other signaling pathways were reviewed in this article. GPC3-targeted therapies, such as monoclonal antibodies, bispecific antibodies, tumor vaccines, immunotoxins, CAR-T cells, and photosensitizer therapy were also summarized. These treatment methods offered promising approaches for HCC treatment and future treatment strategies for HCC based on GPC3 were prospected in this paper.